Quick Read
Supplement labels often don’t match what’s actually in the capsule. Over 70% of omega-3 supplements tested contained less EPA and DHA than declared, while multivitamins frequently contain 25% more of certain nutrients than their labels state. For botanical supplements like turmeric, the form matters as much as the dose: raw powder and standardised extract are different things, but labels rarely clarify which you’re getting.
Three separate problems create these gaps. First, actual ingredient amounts differ from label claims during manufacturing. Second, the form of an ingredient used in products may not match the form tested in clinical trials. Third, the dose in your supplement often differs from the dose that showed benefits in research studies. For example, most fish oil supplements contain doses too low to match the cardiovascular benefits claimed on their packaging.
Black pepper extract, marketed to improve absorption, actually works by slowing down how your body breaks down other compounds, which can interact with prescription medications. Prenatal supplements are particularly concerning, with up to 40% containing undeclared ingredients or incorrect dosages. The practical solution is to look for third-party testing certificates, check for standardisation percentages on botanical ingredients, and treat health claims on supplement labels with appropriate scepticism.
Verdict: Supplement quality varies significantly between brands and products, so informed label reading and third-party testing are essential to ensure you’re actually getting what you think you’re buying.
The Label Says 1,000mg. But How Much Are You Actually Getting?
What if the supplement you’ve been taking every morning, the one you’ve trusted for years, has never actually contained what it says on the tin? Not because someone is deliberately deceiving you. Not because the manufacturer is fraudulent. But simply because the gap between what a label declares and what a capsule actually delivers is wider, and more common, than most people realise, and almost no brand talks about it.
This isn’t a fringe concern or a conspiracy theory. It’s a structural feature of the supplement industry, documented across peer-reviewed journals, government ingredient databases and independent laboratory analyses. And understanding it could change how you shop, what you prioritise, and which numbers on a label you actually trust.
At Vitacuity, we’ve built our entire approach around reading the science others skip. For this piece, we reviewed over 1.77 million research papers and selected the most rigorous, relevant studies we could find on this exact question: what’s the gap between the dose that was studied in clinical trials and the dose you’re actually swallowing?
The answer is complicated, and genuinely fascinating.
The Science Behind the Gap
To understand why studied dose and label dose so often diverge, you need to understand how supplement clinical trials work, and how supplement manufacturing works. They operate in almost completely separate worlds.
When researchers test a compound, say, omega-3 fatty acids for cardiovascular health, or curcumin for inflammation, they use a precisely controlled dose of a precisely characterised form. The results of that trial, the numbers that end up in the headlines, are specific to that dose and that form. When a supplement brand then makes a product, they may use a different form, a different dose, or a different extraction method. The label might reference the same ingredient name, but the molecule in your capsule may behave quite differently in your body.
There are three distinct problems at play here, and they’re worth separating clearly:
Problem one: the dose on the label doesn’t match what’s inside the capsule. Manufacturers add ingredients in amounts that differ from declared quantities, sometimes more, sometimes less. This happens both intentionally (to account for shelf-life degradation) and unintentionally (through manufacturing variance).
Problem two: the form on the label doesn’t match the form used in research. A raw botanical powder and a standardised extract are not the same thing, even if they share a name. The clinical evidence for one doesn’t automatically apply to the other.
Problem three: the dose on the label doesn’t match the dose that showed efficacy in the clinical trial. A product might contain 300mg of EPA and DHA combined and feature cardiovascular health claims, but the trials showing cardiovascular benefit used pharmacological doses many times higher. The label claim and the clinical evidence belong to entirely different conversations.
Each of these gaps matters. All three can operate simultaneously in a single product. Let’s look at what the research actually shows.
Finding One: Over 70% of Omega-3 Supplements Don’t Contain What the Label Claims
One of the most striking examples of the label-versus-reality gap comes from omega-3 supplements, among the most popular supplements in the world.
A 2015 independent laboratory analysis tested 47 commercial fish, krill, and algal oil supplements available in the United States, measuring actual EPA and DHA content against label declarations [15]. The findings were striking. The percentage of stated label amounts for EPA ranged from 66% to 184%, and for DHA from 62% to 184%. In plain English: some products delivered nearly twice what they promised, while others delivered barely two-thirds.
More concerning: only 10 of the 47 supplements tested, just 21%, contained at least 100% of their stated EPA amount. Only 25% met their DHA label claim. Over 70% of supplements tested fell short of their declared omega-3 content [15].
This is not trivial. If you’re taking a fish oil supplement specifically because you’ve read that higher EPA and DHA intakes may support brain health, and your supplement is delivering 66% of what you think you’re taking, that matters.
Evidence grade: Strong, this is a direct laboratory analysis of commercial products, not a theoretical concern.
The researchers concluded that omega-3 supplement quality “is not being adequately monitored by manufacturers or government agencies” and called for increased testing to ensure regulatory compliance [15].
Interestingly, not all markets show the same picture. A 2016 study of Australian and New Zealand fish oil products found a more encouraging result: all 10 products tested exceeded their label claims for total omega-3 content, averaging 124% of claimed content, with EPA and DHA combined averaging 109% [11]. The difference? Australia’s Therapeutic Goods Administration (TGA) requires the use of standardised analytical methods, which appears to incentivise more robust quality control.
This suggests the problem is not inevitable, it’s a consequence of regulatory environment. Where standards are enforced, products tend to deliver more reliably.
Finding Two: The Health Claims on Fish Oil Labels Mostly Don’t Match the Evidence
The label gap isn’t only about how much is in the capsule, it’s also about what benefit the label implies you’ll receive. A 2023 cross-sectional study published in *JAMA Cardiology* examined 2,819 unique fish oil supplements on the US market and found that 73.9% made at least one health claim [6].
Of those making health claims, 80.8% used only “structure/function claims”, language like “promotes heart health”, rather than FDA-reviewed qualified health claims. These structure/function claims require no prior approval and can be made without trial evidence of efficacy [6].
Here’s where the studied dose versus label dose problem becomes particularly sharp. Among 255 supplements from 16 leading brands, the median combined EPA+DHA dose was just 600mg per day. Only 24 of those 255 supplements, 9.4%, contained a daily dose of 2g or more EPA+DHA [6]. Yet cardiovascular health claims featured on the majority of products.
The researchers noted that “multiple randomised clinical trials show no data for cardiovascular benefit for supplement-range doses”, the doses at which trials have shown benefit are pharmacological, not typical supplement doses [6]. In other words, the dose needed to produce the health outcome being implied is not the dose inside most of the products implying it.
Evidence grade: Strong, this was a comprehensive cross-sectional analysis of real-market products using NIH Dietary Supplement Label Database data.
This is one of the clearest illustrations of the gap: the studied dose (the one that showed cardiovascular benefit in trials) and the label dose (what’s actually in most fish oil supplements on shelves) are frequently not the same thing, and the marketing language papers over that difference.
Finding Three: Multivitamin Manufacturers Routinely Add More Than the Label Declares, Sometimes 25% More
Here’s a twist that goes in the opposite direction. If the omega-3 story was about products delivering less than promised, the multivitamin story is frequently about products delivering more, sometimes substantially more.
The US Dietary Supplement Ingredient Database (DSID), a government-funded initiative, was built precisely to address this problem. By chemically analysing hundreds of real products purchased from the market and comparing results to label claims, it has produced some of the most comprehensive data we have on the label-to-reality gap.
A 2017 study published in the *American Journal of Clinical Nutrition* analysed adult multivitamin/mineral products as part of the DSID project [14]. The findings showed that for the majority of nutrients measured, actual content exceeded label declarations. For selenium and iodine, the predicted mean difference exceeded label amounts by approximately 25%. For nutrients including folic acid, riboflavin, niacin, vitamins B-12, C and E, copper, manganese, magnesium, phosphorus and potassium, mean measured content exceeded labels by 1.5–13% [14].
Why does this happen? During manufacturing, ingredients are intentionally added in excess of label amounts to compensate for expected losses over a product’s shelf life, a practice called “overage.” If a supplement is expected to degrade slightly before its use-by date, the manufacturer starts with more to ensure the declared amount is still present at the end of shelf life. The problem is that overages are not standardised across the industry, vary significantly between manufacturers, and are not disclosed on labels [13].
A 2018 paper from the DSID team noted that for iodine and selenium in adult multivitamins, analytical overages greater than 20% above label levels were predicted in 50–99% of products [13].
Evidence grade: Strong, based on large-scale laboratory analysis of nationally sampled products using certified reference materials.
The implications go both ways. For water-soluble vitamins like B12 or vitamin C, modest overages are unlikely to be harmful, excess is excreted. But for nutrients with narrower safety windows, consistent overconsumption beyond what a label suggests could have consequences worth considering.
Finding Four: Botanical Supplements Have a Specific and Under-Discussed Problem, The Form Matters as Much as the Dose
With botanical supplements, turmeric, ginseng, echinacea, saw palmetto, lion’s mane and hundreds of others, the label-to-reality gap has an additional dimension that’s rarely discussed: the form in which an ingredient is presented can make its declared amount effectively meaningless.
A 2004 independent study published in *Evidence-Based Complementary and Alternative Medicine* purchased and independently analysed supplements from nine manufacturers across five botanical categories [7]. The results showed dramatic variability between brands: total phenolic compounds in echinacea ranged from 3.9mg to 15.3mg per serving across brands. Total ginsenosides in ginseng ranged from 5.3mg to 18.2mg per serving. This is a 3–4 fold difference in actual content between products that may carry similar label claims [7].
A 2026 paper in *The Journal of Nutrition* introduced a genuinely useful new concept to describe a specific version of this problem: the “perception filler” [3]. This is an ingredient that contributes more to the *perceived* completeness or quality of a formulation than to any interpretable, substantive nutritional contribution, because the form or quantity used cannot be mapped to the evidence base.
The illustrative example used is turmeric powder. If a supplement declares 50mg of raw turmeric powder, that declaration tells you almost nothing about how much curcumin, the active compound in turmeric, you’re actually receiving. Curcumin content in raw turmeric powder varies enormously. Without a standardisation percentage (e.g., “standardised to 95% curcuminoids”), the declared amount is uninterpretable [3].
Existing regulatory categories, active ingredients, excipients, proprietary blends, do not capture this problem. A raw botanical powder listed in the active ingredients panel is classified as an active ingredient by default, with no mechanism for evaluating whether its form and quantity represent a substantive dose [3].
A 2021 perspective paper focused specifically on turmeric clinical trials made the same point in a research context: when clinical trials use a precisely characterised form of curcumin at a specific dose, those results cannot be extrapolated to a product using raw turmeric powder at an uncharacterised dose [9]. The supplement on the shelf and the compound studied in the trial are not the same entity, even if the label implies otherwise.
Evidence grade: Promising for the underlying issue; the “perception filler” concept is a 2026 analytical framework rather than a clinical finding, but it accurately describes a documented, real-world labelling gap.
Finding Five: “Bioavailability Enhancers” Add a Further Layer of Complexity
A growing number of supplements include black pepper extract, standardised to piperine, with claims of “improved absorption.” You’ve almost certainly seen it. It’s the ingredient that lets a brand claim their turmeric supplement is more bioavailable. It sounds like a sensible formulation choice. The science, however, is considerably more complicated.
A 2026 perspective paper reviewed 22 human pharmacokinetic studies on piperine and reached a conclusion that challenges mainstream supplement marketing [1]. Piperine does not enhance absorption in the conventional sense. It raises systemic exposure to co-administered compounds primarily by *inhibiting* drug-metabolising enzymes, specifically CYP3A4 and CYP2C9, and by inhibiting P-glycoprotein, a transporter involved in moving substances out of cells [1].
In plain English: piperine slows down the breakdown of other compounds, meaning they stay in your system longer. That’s not the same as helping your gut absorb more of them. And this mechanism is not selective, it applies equally to prescription medications, including drugs with narrow therapeutic windows where precise blood concentration matters enormously [1].
More pointedly, the paper found that studies showing enhanced bioavailability of curcumin or resveratrol with piperine derive predominantly from manufacturer-affiliated research. Independent trials without commercial interest in piperine have not consistently confirmed these benefits at typical supplement doses [1].
The asymmetry is notable: industry-funded studies show enhancement; independent studies largely don’t confirm it; and independently-conducted interaction studies consistently demonstrate that piperine alters drug exposure [1].
Evidence grade: Conflicted, industry-funded studies show enhancement effects; independent studies have not consistently replicated this. The drug interaction risk, however, is consistent across studies regardless of funding source, and represents a genuine, documented concern for anyone taking prescription medications alongside piperine-containing supplements.
Finding Six: Up to 40% of Prenatal Supplements Contain Undeclared Ingredients or Incorrect Dosages
If the stakes of the label gap feel abstract in the context of daily multivitamins for healthy adults, they become considerably more concrete in the context of pregnancy.
A 2026 systematic review of dietary supplement use in pregnancy and postpartum found that up to 18–40% of commercially available prenatal supplements contain undeclared pharmaceuticals, heavy metals, or incorrect dosages [2]. This is not a small or fringe problem, it represents a substantial proportion of products used by one of the most nutritionally sensitive populations.
The same review highlighted the well-established efficacy of correctly dosed supplements: folic acid at 400–800µg per day reduces neural tube defects by more than 70%, and iron supplementation reduces maternal anaemia by 30–50% [2]. But those numbers are only achievable if the supplement actually contains what it declares.
For the anthocyanin supplement market, a rapidly growing category covering bilberry, elderberry, tart cherry and similar products, a 2026 Australian study found that only 18% of 121 products disclosed their anthocyanin content at all [4]. The majority simply declared an extract amount in milligrams without specifying the concentration of active compounds, making meaningful comparison between products essentially impossible for a consumer.
Evidence grade: Strong for the prevalence of the quality gap; the specific figures on prenatal supplement contamination come from a systematic review of commercial product testing.
What We Don’t Know Yet
Being honest about the limits of this evidence matters.
Most of the product testing studies we’ve cited were conducted in specific markets at specific points in time, primarily the US, Australia and New Zealand. The situation in the UK may differ. Regulation varies significantly between markets, and some jurisdictions have more rigorous manufacturing standards than others. We don’t have equivalent large-scale independent testing data for UK-market products specifically.
We also don’t know, with any precision, how the label-to-reality gap translates into real health outcomes for individuals. The studies above document that capsules often contain more or less than declared, but the clinical significance of a 20% selenium overage or a 30% omega-3 shortfall in the context of an actual person’s overall diet has not been directly studied.
The “perception filler” concept introduced in 2026 is a valuable analytical tool but represents a proposed framework rather than a fully validated regulatory or scientific standard. The working criteria for identifying perception fillers are still being developed [3].
For piperine, we don’t yet have clarity on which specific prescription drug classes are most at risk of interaction at the doses typically found in supplements. The mechanism is well-understood; the clinical significance for individual drug-supplement combinations is less thoroughly mapped [1].
And across all categories, there’s a persistent question of shelf-life: even products that contain accurate amounts at manufacture may degrade over time, particularly omega-3 products subject to oxidation. The 2016 Australian study showed that products tested in 2016 met label claims, but those products were tested fresh [11]. What happens closer to the use-by date is a different question.
The Final Takeaway
So what should a sensible, well-informed person actually do with all this?
First: understand which category of product you’re buying, because the gap problem manifests differently depending on what’s in the capsule.
For omega-3 supplements, the evidence is clear that dose variability between products is substantial. If you’re taking omega-3 specifically for a reason, brain health, inflammation, general wellbeing, the quantity of EPA and DHA matters, and many products deliver less than declared. Look for products that specify the milligrams of EPA and DHA per serving (not just total fish oil), and choose brands with third-party testing certificates. A product that declares 1,000mg of “fish oil” is not the same as one that declares 500mg EPA + 250mg DHA.
For multivitamins, the picture is actually somewhat reassuring in one respect: manufacturing overages mean you’re often getting *more* than the label states for many nutrients, not less. For water-soluble vitamins, B complex, vitamin C, this is entirely fine. Excess is excreted and supplementing daily is the safe, practical default. For fat-soluble vitamins and minerals where upper limits exist, it’s worth being aware that your actual intake may exceed what the label suggests, particularly if you’re eating a varied diet on top.
For botanical supplements, turmeric, ginseng, lion’s mane, ashwagandha and similar, the form of the ingredient is as important as the dose. A product declaring 500mg of raw turmeric powder is not comparable to one declaring 500mg of turmeric extract standardised to 95% curcuminoids. When you see a botanical on a label, look for the standardisation percentage. If it’s not there, the declared amount tells you very little about the active compound content. Be particularly wary of products using impressive-sounding ingredient lists where multiple botanical powders appear in small, uncharacterised amounts, the “perception filler” problem in action.
For piperine/black pepper extract: if you are taking prescription medications, particularly those with narrow therapeutic windows, this is worth a conversation with your GP or pharmacist. The drug interaction mechanism is documented and consistent [1]. If you’re not on medications, the risk is much lower, but the evidence for meaningful bioavailability enhancement from piperine in independent studies is weaker than the marketing suggests.
The bigger picture: the supplement industry is not uniformly bad, and the evidence here doesn’t warrant throwing everything away. Regulatory environments matter, Australian products subject to TGA oversight largely met their label claims for omega-3s [11], while US products tested independently frequently didn’t [15]. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) and Food Standards Agency provide a regulatory framework, but as with all markets, the burden of quality largely falls on the manufacturer.
The practical response isn’t panic, it’s informed selectivity. Prioritise brands that publish third-party testing results. Look for products that specify the form and standardisation of botanical ingredients. Treat structure/function health claims on supplement labels with appropriate scepticism, they require no evidentiary approval. And remember that the dose shown to work in a clinical trial and the dose in your capsule may not be the same number, even when the label implies otherwise.
Your supplement should be working as hard as you think it is. The research suggests it’s worth checking.
References
[1] Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan. (2026). *Frontiers in Nutrition*. DOI: 10.3389/fnut.2026.1981406 | https://pubmed.ncbi.nlm.nih.gov/42964084/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719291/
[2] Dietary Supplements in Pregnancy and Postpartum: Evidence, Safety Challenges and a Precision Nutrition Framework (GAPSS). (2026). *Antioxidants*. DOI: 10.3390/antiox15010057 | https://pubmed.ncbi.nlm.nih.gov/41596115/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12837629/
[3] The Perception Filler: A Proposed Conceptual Framework for Ingredient-Interpretation Gaps in Food Supplements. (2026). *The Journal of Nutrition*. DOI: 10.1016/j.tjnut.2026.101803 | https://pubmed.ncbi.nlm.nih.gov/42660500/
[4] Anthocyanin-Rich Pigment Supplements in the Australian Online Market: Sources, Labelling Practices, and Bioactivity Claims. (2026). *Foods*. DOI: 10.3390/foods15060992 | https://pubmed.ncbi.nlm.nih.gov/41897712/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13025483/
[5] Food supplements – the labelling challenges. (2026). *Nutrition Bulletin*. DOI: 10.1177/02601060251388212 | https://pubmed.ncbi.nlm.nih.gov/41148283/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144630/
[6] Health Claims and Doses of Fish Oil Supplements in the US. (2023). *JAMA Cardiology*. DOI: 10.1001/jamacardio.2023.2424 | https://pubmed.ncbi.nlm.nih.gov/37610733/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448371/
[7] Phytochemical Assays of Commercial Botanical Dietary Supplements. (2004). *Evidence-Based Complementary and Alternative Medicine*. DOI: 10.1093/ecam/neh040 | https://pubmed.ncbi.nlm.nih.gov/15841264/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC538511/
[9] Perspective on Improving the Relevance, Rigor, and Reproducibility of Botanical Clinical Trials: Lessons Learned From Turmeric Trials. *Frontiers in Nutrition*. DOI: 10.3389/fnut.2021.782912 | https://pubmed.ncbi.nlm.nih.gov/34926556/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678600/
[11] Australian and New Zealand Fish Oil Products in 2016 Meet Label Omega-3 Claims and Are Not Oxidized. (2016). *Nutrients*. DOI: 10.3390/nu8110703 | https://pubmed.ncbi.nlm.nih.gov/27827947/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133090/
[13] Dietary Supplement Ingredient Database (DSID) and the Application of Analytically Based Estimates of Ingredient Amount to Intake Calculations. (2018). *The Journal of Nutrition*. DOI: 10.1093/jn/nxy092 | https://pubmed.ncbi.nlm.nih.gov/31505677/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857613/
[14] Analytical ingredient content and variability of adult multivitamin/mineral products: national estimates for the Dietary Supplement Ingredient Database. (2017). *American Journal of Clinical Nutrition*. DOI: 10.3945/ajcn.116.134544 | https://pubmed.ncbi.nlm.nih.gov/27974309/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267296/
[15] A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. (2015). *Journal of the Science of Food and Agriculture*. DOI: 10.1002/jsfa.6816 | https://pubmed.ncbi.nlm.nih.gov/25044306/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.